halcinonide and Dermatitis--Atopic

Thirty-three patients with acute or subacute eczematous dermatitis were treated for two weeks in a double-blind, parallel-group study to compare the efficacy and cosmetic acceptability of 0.1 percent amcinonide cream and 0.1 percent halcinonide cream. Patients in both treatment groups showed significant (p less than 0.05) improvement from baseline for most signs and symptoms at the three evaluation times (days 3, 7, and 14). Comparisons between groups showed no significant differences at any evaluation except at day 14, when the amicinonide-treated patients had significantly (p = 0.04) less edema. The physician's evaluations were not significantly different except at day 7, when the halcinonide patients showed significantly (p = 0.04) more overall improvement. The patients' overall evaluations were not significantly different at any time. In general, both creams were cosmetically acceptable. At day 3, seven amcinonide patients noted skin tightening compared to one halcinonide patient; four halcinonide patients (as well as two at day 7 and one at day 14) reported stinging compared to only one amcinonide patient. In addition, two halcinonide patients reported a burning sensation at one or more evaluations compared to no such reports from amcinonide patients. One other side effect, a metallic taste in the mouth, occurred in a halcinonide-treated patient.

Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Clinical Trials as Topic; Dermatitis, Atopic; Double-Blind Method; Female; Halcinonide; Humans; Male; Middle Aged; Ointments; Pregnenediones; Random Allocation; Triamcinolone

Six groups of children suffering from widespread atopic dermatitis were treated once daily with six topical steroids of different potency. Systemic effects were measured by the morning estimation of plasma cortisol. A clear relationship was demonstrated between clinical efficacy of the steroid treatment and degree of reduced adrenal function. This study demonstrated that a rapid and marked therapeutic effect can be obtained with potent topical steroids applied once daily without occlusion, but in children is accompanied by a fall in plasma cortisol.

Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Child; Child, Preschool; Clobetasol; Dermatitis, Atopic; Desonide; Diflucortolone; Drug Administration Schedule; Female; Fluocortolone; Halcinonide; Humans; Hydrocortisone; Infant; Male; Ointments

The efficacy of short-term treatment of acute exacerbations of atopic dermatitis with a corticosteroid ointment (halcinonide, 0.1 percent) was demonstrated by comparing such a formulation with its ointment base (placebo). A double-blind, paired comparison study was conducted in 214 patients. Within two weeks the therapeutic response was judged excellent in 137 (64 percent) of the patients receiving the corticosteroid treatment. The number of responses judged good to excellent was 182 (85 percent). With the placebo, there was an excellent response in 50 (23 percent) of the patients and the number judged good to excellent was 95 (44 percent). Although these placebo responses attested to the appropriateness of a highly occlusive ointment vehicle in this condition, the corticosteroid containing formulation was superior (p less than 0.001). In only 10 (5 percent) of the patients was there a poor response to corticosteroid treatment. direct comparison of the response of similar bilateral lesions showed the corticosteroid to be superior to the placebo in 147 (69 percent) patients and the placebo to be superior in just 31 (15 percent) (p less than 0.001). No adverse reactions occurred with either preparation. We conclude that in the management of atopic dermatitis, full advantage should be taken of short-term corticosteroid therapy (preferably in ointment form), which is virtually free of those potential unwanted effects of chronic therapy with this class of drugs.

Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis, Atopic; Female; Halcinonide; Humans; Male; Middle Aged; Ointments; Pharmaceutical Vehicles; Pregnenediones

A double-blind paired comparison was made of once daily and three times daily regimens of 0.1% halcinonide cream in 149 patients with atopic dermatitis and 194 with psoriasis. In a simultaneously conducted study once daily application of 0.1% halcinonide was compared to the cream base alone (placebo) in 48 patients with atopic dermatitis and 78 with psoriasis. Results show that a once daily regimen can be an effective treatment in both conditions, and can be recommended as a starting regimen in certain circumstances such as the treatment of young children or pregnant women, or where long-term treatment is likely. The three times daily regimen, however, was superior overall, and is still recommended as the treatment of choice, at least in severe psoriasis.

Topics: Administration, Topical; Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis, Atopic; Double-Blind Method; Female; Halcinonide; Humans; Infant; Male; Middle Aged; Pregnenediones; Psoriasis

Seventy-nine patients with atopic dermatitis were treated in a double-blind paired comparison fashion with halcinonide cream (0.025%) or its placebo control. The overall therapeutic response was excellent in thirty-seven (47%) patients treated with halcinonide cream (0.25%) as compared with twenty-two (28%) patients treated with the placebo cream. In the comparative response, halcinonide was considered superior in forty-six (58%) patients, and the placebo was considered superior in fifteen (19%). Statistically, halcinonide cream was shown to be significantly superior to the placebo cream (p less than 0.001). Side effects noted in five patients included burning, stinging, and pain, due in most cases to both halcinonide and the placebo cream.

Topics: Administration, Topical; Adolescent; Child; Child, Preschool; Dermatitis, Atopic; Double-Blind Method; Female; Halcinonide; Humans; Infant; Male; Placebos; Pregnenediones

In a double-blind multi-centre study, comprising ninety-five patients with psoriasis and atopic dermatitis, 0.1% halcinonide cream applied once daily was equally as effective as the cream applied three times daily. However, the onset of action was more rapid when the cream was applied three times daily. In a control study once daily application of 0.1% halcinonide cream was found to be superior to the vehicle alone in the treatment of forty patients with the same diseases.

Topics: Administration, Topical; Adolescent; Adult; Aged; Child; Child, Preschool; Clinical Trials as Topic; Dermatitis, Atopic; Double-Blind Method; Drug Administration Schedule; Evaluation Studies as Topic; Female; Halcinonide; Humans; Infant; Male; Middle Aged; Placebos; Pregnenediones; Psoriasis; Time Factors

Data were reviewed on the beneficial responses and adverse reactions among 2,849 patients in 14 paired-comparison studies with eight unoccluded topical corticosteroids in six steroid-responsive dermatoses. Adverse reactions were found to be mild, transient, and, for the most part, rare. Of 5,698 treatment exposures, 249 (4.39%) adverse reactions were reported, including irritation (1.3%), itching (0.95%), burning (0.81%), dryness (0.46%), scaling (0.30%), and vesicle formation (0.16%). Other reactions occurred in less than one in 1,000 treatment exposures. No severe reactions were observed. Five subjects (0.17%) terminated treatment early because of adverse reactions. The incidence of adverse reactions to vehicle alone was 6.7%. The benefit-risk ratio for mild reactions was 17:1. Therefore, long lists of adverse reactions are inappropriate in written consent forms for prospective volunteers for clinical trials. Al alternative warning statement is proposed.

Topics: Administration, Topical; Anti-Inflammatory Agents; Clinical Trials as Topic; Dermatitis, Atopic; Dermatitis, Contact; Double-Blind Method; Female; Fluocinonide; Glucocorticoids; Halcinonide; Humans; Male; Psoriasis; Skin Diseases

A study showing the superiority of fluocinonide (0.05 percent) cream over halcinonide (0.1 percent) cream in the treatment of atopic dermatitis is presented herein.

Topics: Adult; Aged; Child, Preschool; Clinical Trials as Topic; Dermatitis, Atopic; Double-Blind Method; Drug Evaluation; Female; Fluocinolone Acetonide; Fluocinonide; Halcinonide; Humans; Male; Pregnenediones

The purpose of this article is to acquaint the pediatrician with polymorphic light eruption (PMLE) a light-induced, eczematous, cutaneous reaction that frequently begins in childhood. This sun-induced eruption is frequently misdiagnosed because of its similarity to atopic dermatitis.

Topics: Child; Dermatitis, Atopic; Diagnosis, Differential; Diphenhydramine; Drug Therapy, Combination; Halcinonide; Humans; Male; Photosensitivity Disorders; Sunscreening Agents